BullFrog AI

BullFrog AI is an artificial intelligence-driven biopharma technology company focused on accelerating drug discovery and clinical development. Leveraging explainable AI, graph analytics, and data harmonization tools, BullFrog AI applies next-generation predictive analytics across all stages of drug development — from discovery and preclinical research through clinical trials — with the goal of getting safer, more effective therapies to market faster and at reduced cost. The company's overarching mission is precision medicine: finding the right patient for the right drug at the right dose.

Led by CEO Vin Singh, a recipient of the Top 50 AI CEOs Award in 2021 from Technology Innovators, BullFrog AI combines high-performance technology with deep domain expertise. The company's platforms are designed to complement biopharma partners at every stage of their R&D pipeline, optimizing translational insights and improving the likelihood of clinical success.

Core Platform Products

• bfPREP™ — Data Harmonization Platform: bfPREP™ transforms raw, fragmented biomedical data into clean, harmonized, AI-ready assets. It supports data extraction, feature engineering, and schema design, enabling teams to prepare clinical trial data for analysis, harmonize multi-omics and clinical datasets, and accelerate data readiness for reliable AI/ML drug target discovery. A notable case study demonstrates the conversion of 10,000+ PDF scans into actionable, structured data.
• bfLEAP® — Biomedical Data Analysis Platform: bfLEAP® uncovers biologically meaningful patterns, subgroups, and drivers hidden within complex, multimodal datasets. Using BullFrog Data Networks®, the platform quantifies similarities and differences across patients, cohorts, and conditions. Key capabilities include identifying responder and non-responder patient subgroups, discovering novel drug targets and biomarkers, understanding disease heterogeneity and mechanisms, and optimizing translational insights from preclinical to clinical stages. Research utilizing bfLEAP® has been presented at major conferences, including work on identifying drug response subgroups at ASCO GI 2026.
• AI Decision Support Platform (Coming Soon): This forthcoming platform is designed to convert biological insight into ranked, explainable decisions that drive portfolio confidence. Planned capabilities include prioritizing drug targets and development programs, supporting indication selection and trial design decisions, ranking portfolio options by scientific and clinical impact, and building diversified, risk-balanced R&D portfolios.

Key Capabilities and Analytical Approach

• Explainable AI that delivers driver-level insights, making analytical outputs transparent and defensible
• Graph analytics through BullFrog Data Networks® for interrogating complex biological relationships
• Multi-step data processing pipeline: data cleaning, unit normalization, feature engineering, and dataset standardization
• Subgroup identification and patient clustering to support precision medicine strategies
• Artifact filtering to remove noise and outliers from biomedical datasets
• Multivariate analytical approach applied across discovery, preclinical, and clinical development stages

Thought Leadership and Resources

• Published whitepapers including Data Harmonization: The Hidden Prerequisite for Reliable AI/ML in Life Sciences (January 2026) and AI in Bioinformatics: Turning Complex Data Into Actionable Insights with BullFrog Data Networks® (October 2025)
• Active webinar program covering topics such as turning AI recommendations into clear, defensible decisions and drug development prioritization strategies
• Executive visibility including presentations at RedChip's AI Conference
• Free bfPREP™ audits and platform walkthroughs available for prospective customers

BullFrog AI serves biopharma organizations seeking to harness AI-driven analytics to improve clinical research outcomes, reduce development risk, and advance the field of precision medicine.